Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

250 articles with Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

• 

  Clinical Catch-Up: February 17-21

  2/24/2020

  Mid-February had a solid number of clinical trial announcements. Here’s a look.
• 

  Clinical Catch-Up: December 16-20

  12/23/2019

  Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
• 

  ASH Roundup: Bristol-Myers Squibb, bluebird bio, Oryzon and More

  12/10/2019

  As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
• 

  Clinical Catch-Up for September 31-October 4

  10/7/2019

  It was another busy week for clinical trials. Here’s a look.
• 

  Clinical Catch-Up: September 16-20

  9/23/2019

  Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.

• Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

  7/9/2019

  Cellectar Biosciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation for CLR 131 in relapsed or refractory Diffuse Large B-Cell Lymphoma.

• Cellectar Initiates DLBCL Cohort in Phase II Trial of CLR 131 in Refractory B-Cell Hematologic Cancers

  1/29/2018

  The Company expects to enroll up to 10 patients with DLBCL into this cohort prior to conducting an interim analysis.

• 

  Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations

  1/9/2018

  Cellectar Biosciences is closing its manufacturing operations and contracting them out.

• Cellectar Files IND for Phase I Trial of CLR 131 in Pediatric Cancers

  12/14/2017

  The study will be initiated with the pediatric oncologists and Nuclear Medicine/Radiology Group at The University of Wisconsin Carbone Cancer Center.

• Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase II Trial of CLR 131

  12/6/2017

  Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit.

• Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance

  11/10/2017

  Cash and cash equivalents as of September 30, 2017 were approximately $5.7 million compared to approximately $11.4 million as of December 31, 2016.

• Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase I Trial in Advanced Multiple Myeloma

  11/7/2017

  While no head-to-head studies have been conducted for comparison, the median overall survival benefit seen with the three most recently FDA-approved third line therapies for multiple myeloma ranges from 11.9 – 18.6 months in separate trials.

• Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance

  11/2/2017

  The live and archived webcast can be accessed via the company’s website

• New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination With External Radiation

  10/30/2017

  Investigators observed that CLR 127 was taken up and retained in the tumor cells at 6-10 fold higher level than normal tissue and sensitized the tumor cells to external radiation.

• Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma

  10/24/2017

  In September, the trial's Data Monitoring Committee (DMC) determined that the fourth cohort single dose of 31.25 mCi/m2 was safe and tolerated.

• Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors

  10/17/2017

  The Japanese Patent Office has granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125.

• Cellectar Biosciences Announces Successful Completion Of $7.76 Million Registered Direct Offering

  10/12/2017

• Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market

  10/11/2017

• Cellectar Biosciences And Pierre Fabre Extend Collaboration For Development Of New Phospholipid Drug Conjugates

  10/10/2017